×
Including results for dynavax investor relations
Search only for dvax investor relations
Dynavax is a commercial-stage biopharmaceutical company built on the foundation of our significant experience and expertise in vaccine development and ...
People also ask
Dynavax Technologies is focused on leveraging the power of the body's innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.
Feb 22, 2024 · Total revenues for the fourth quarter of 2023 were $55.6 million, compared to $184.5 million for the fourth quarter of 2022, and $232.3 million ...
8 days ago · EMERYVILLE, Calif., April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ... investors.dynavax.com/events-presentations.
Nov 3, 2023 · I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin ...
Nov 2, 2023 · HEPLISAV-B vaccine net product revenue was $62.3 million for the third quarter of 2023, compared to $37.5 million for the third quarter of 2022, ...
Feb 23, 2024 · I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin ...